Other studies have confirmed that high BMAL1 expression is associated with increased sensitivity of colorectal cancer cells to oxaliplatin (DNA/RNA synthesis inhibitor) and predicts favorable outcomes for patients treated with oxaliplatin-based chemotherapy (Zeng et al., 2014). The gene discussed is BMAL1; the disease is colorectal cancer.